Engineering Bacteria as Living Therapeutics in Cancer Therapy.

Area of Science:

• Synthetic biology
• Microbial therapeutics
• Oncology

Background:

• Cancer remains a leading global cause of death, with conventional treatments like chemotherapy exhibiting significant limitations.
• Synthetic biology advancements allow for the engineering of biological systems, including bacteria, for therapeutic applications.
• Engineered bacteria offer novel strategies for cancer treatment, including targeted delivery and modulation of the tumor microenvironment.

Purpose of the Study:

• To review and discuss the recent advancements in using engineered bacteria as cancer therapeutics.
• To highlight the capabilities of engineered bacteria in tumor targeting, microenvironment modulation, and drug delivery.
• To identify current challenges and future opportunities in the field of bacterial cancer therapy.

Main Methods:

• Review of recent literature on synthetic biology applications in cancer therapy.
• Analysis of engineered bacterial systems for tumor targeting and drug release.
• Discussion of challenges and future directions in microbial cancer therapeutics.

Main Results:

• Engineered bacteria can be designed for precise tumor targeting.
• These bacteria can modulate the tumor microenvironment to enhance therapeutic efficacy.
• Bacterial platforms facilitate controlled anticancer drug release directly at the tumor site.

Conclusions:

• Engineered bacteria represent a promising frontier in cancer therapy, offering targeted and localized treatment strategies.
• Overcoming challenges in delivery, safety, and efficacy is crucial for clinical translation.
• Continued innovation in synthetic biology will likely expand the potential of microbial therapeutics in oncology.